{"id":1736,"date":"2024-01-19T10:26:12","date_gmt":"2024-01-19T13:26:12","guid":{"rendered":"https:\/\/beritpress.com.br\/?p=1736"},"modified":"2024-01-19T10:26:14","modified_gmt":"2024-01-19T13:26:14","slug":"laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus","status":"publish","type":"post","link":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/","title":{"rendered":"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"613\" src=\"http:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil-1024x613.jpg\" alt=\"\" class=\"wp-image-1737\" srcset=\"https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil-1024x613.jpg 1024w, https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil-300x179.jpg 300w, https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil-768x459.jpg 768w, https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil.jpg 1170w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption>Foto: Marcello Casal Jr.\/Ag\u00eancia Brasil<\/figcaption><\/figure><\/div>\n\n\n\n<p>Fam\u00edlias de crian\u00e7as com neuroblastoma com necessidade de acesso ao medicamento de alto custo betadinutuximabe (que tem o nome comercial Qarziba) podem ter novidades neste ano.&nbsp;O laborat\u00f3rio farmac\u00eautico Recordati divulgou que submeteu esta semana&nbsp;o rem\u00e9dio \u00e0 avalia\u00e7\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (Conitec). Se aprovado, o medicamento passa a fazer parte do&nbsp;<a href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2024-01\/neuroblastoma-familias-compartilham-dificuldades-no-acesso-remedios\" target=\"_blank\" rel=\"noreferrer noopener\">sistema p\u00fablico e atender&nbsp;crian\u00e7as com esse tipo de tumor maligno<\/a>.&nbsp;<img decoding=\"async\" src=\"https:\/\/agenciabrasil.ebc.com.br\/ebc.png?id=1576956&amp;o=node\"><img decoding=\"async\" src=\"https:\/\/agenciabrasil.ebc.com.br\/ebc.gif?id=1576956&amp;o=node\"><\/p>\n\n\n\n<p>Agora, a Conitec tem o prazo de 180 dias (prorrog\u00e1veis por mais 90 dias) para a an\u00e1lise da proposta. Um caso que ficou conhecido da doen\u00e7a recentemente foi o do&nbsp;<a href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2024-01\/saiba-mais-sobre-cancer-que-acomete-filho-de-bruno-pereira\" target=\"_blank\" rel=\"noreferrer noopener\">menino Pedro<\/a>, de 5 anos de idade, filho da antrop\u00f3loga&nbsp;Beatriz Matos e do indigenista Bruno Pereira, assassinado em 2022. O neuroblastoma \u00e9 o terceiro tipo de c\u00e2ncer infantil mais recorrente e representa de 8% a 10% de todos os tumores infantis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Incid\u00eancia<\/h2>\n\n\n\n<p>H\u00e1 uma estimativa de surjam&nbsp;387 novos casos de neuroblastoma no Brasil por ano, e, ao menos, metade estariam classificados como neuroblastoma de alto risco (HRNB).&nbsp;<\/p>\n\n\n\n<p>\u201cReafirmamos nosso compromisso de constru\u00e7\u00e3o para acesso p\u00fablico pleno desta imunoterapia\u201d, apontou o laborat\u00f3rio em nota. No documento, a empresa defendeu que o medicamento \u00e9 recomendado para neuroblastoma de alto risco por ag\u00eancias internacionais de avalia\u00e7\u00e3o de tecnologias de sa\u00fade como do Reino Unido, da Esc\u00f3cia, da Irlanda, da B\u00e9lgica, da Su\u00e9cia, da Pol\u00f4nia, da Austr\u00e1lia, de Taiwan e de Hong Kong para o tratamento dos pacientes.<\/p>\n\n\n\n<p>No Brasil, a Anisa autorizou o uso do medicamento em 2021, mas sem aprova\u00e7\u00e3o da Conitec, o tratamento s\u00f3 \u00e9 poss\u00edvel na rede privada.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Indica\u00e7\u00f5es&nbsp;<\/h2>\n\n\n\n<p>O rem\u00e9dio, conforme defende o laborat\u00f3rio, \u00e9 indicado para pacientes a partir dos 12 meses, e que j\u00e1 foram tratados com quimioterapia de indu\u00e7\u00e3o \u201ce que tenham alcan\u00e7ado pelo menos uma resposta parcial, seguida de terap\u00eautica mieloablativa e transplante de c\u00e9lulas tronco; bem como em pacientes com hist\u00f3ria de recidiva ou neuroblastoma refrat\u00e1rio, com ou sem doen\u00e7a residual\u201d.&nbsp;<\/p>\n\n\n\n<p>O Qarziba, conforme argumenta a empresa farmac\u00eautica, foi utilizado em estudos cl\u00ednicos desde 2009 em 126 centros em mais de mil&nbsp;pacientes em 18 pa\u00edses. \u201cA imunoterapia anti-GD2, como \u00e9 o Qarziba, n\u00e3o apenas melhora a sobrevida, como tamb\u00e9m reduz o risco de que todos os tratamentos anteriores pelos quais esses pacientes passam falhem com recidiva\u201d.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Evolu\u00e7\u00e3o da ci\u00eancia<\/h2>\n\n\n\n<p>Em reportagem publicada pela\u00a0<strong>Ag\u00eancia Brasil<\/strong>\u00a0no \u00faltimo dia 5, a\u00a0oncologista Arissa Ikeda, do Instituto Nacional do C\u00e2ncer, contextualizou que, na \u00faltima d\u00e9cada principalmente, existiu um grande esfor\u00e7o para a melhoria dos tratamentos dessas crian\u00e7as.\u00a0<\/p>\n\n\n\n<p>O tratamento \u00e9 considerado pela m\u00e9dica uma evolu\u00e7\u00e3o importante no tratamento contra o neuroblastoma. Ela explica que os tratamentos mais longos envolvem per\u00edodos de oito meses a mais de um ano.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Dificuldades<\/h2>\n\n\n\n<p><a href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2024-01\/neuroblastoma-familias-compartilham-dificuldades-no-acesso-remedios\" target=\"_blank\" rel=\"noreferrer noopener\">Fam\u00edlias t<\/a><a href=\"http:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2024-01\/neuroblastoma-familias-compartilham-dificuldades-no-acesso-remedios\" target=\"_blank\" rel=\"noreferrer noopener\">\u00eam relatado&nbsp;as dificuldades<\/a>&nbsp;de terem acesso a esses medicamentos de alto custo.&nbsp;Muitas vezes, \u00e9 necess\u00e1rio recorrer a vaquinhas para conseguir arrecadar os recursos, j\u00e1 que o pedido a planos de sa\u00fade ou \u00e0 rede p\u00fablica por meio da&nbsp;Justi\u00e7a \u00e9&nbsp;demorado.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Avalia\u00e7\u00e3o<\/h2>\n\n\n\n<p>Na semana passada, o minist\u00e9rio da Sa\u00fade divulgou que \u201cacompanha e apoia com o m\u00e1ximo interesse as pesquisas e os avan\u00e7os tecnol\u00f3gicos para tratamentos que podem ser incorporados ao SUS\u201d.&nbsp;<\/p>\n\n\n\n<p>At\u00e9 aquele momento, o governo havia divulgado que nenhuma empresa havia solicitado incorpora\u00e7\u00e3o de novo medicamento para tratamento da neuroblastoma no SUS. \u201cA pasta j\u00e1 se reuniu com o laborat\u00f3rio fabricante para demonstrar a possibilidade de an\u00e1lise pela Conitec e est\u00e1 pronta para iniciar o processo de avalia\u00e7\u00e3o, assim que a empresa solicitar a incorpora\u00e7\u00e3o\u201d, explicou o minist\u00e9rio na ocasi\u00e3o.\u00a0<\/p>\n\n\n\n<p>Fonte: <a href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2024-01\/laboratorio-submete-remedio-para-cancer-infantil-aprovacao-do-sus\">Ag\u00eancia Brasil<\/a>. Foto: <a href=\"https:\/\/agenciabrasil.ebc.com.br\/saude\/noticia\/2024-01\/laboratorio-submete-remedio-para-cancer-infantil-aprovacao-do-sus#\">Marcello Casal Jr.\/Ag\u00eancia Brasil<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fam\u00edlias de crian\u00e7as com neuroblastoma com necessidade de acesso ao medicamento de alto custo betadinutuximabe (que tem o nome comercial Qarziba) podem ter novidades neste ano.&nbsp;O laborat\u00f3rio farmac\u00eautico Recordati divulgou que submeteu esta semana&nbsp;o rem\u00e9dio \u00e0 avalia\u00e7\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (Conitec). Se aprovado, o medicamento passa &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/\" class=\"more-link\">Continue lendo<span class=\"screen-reader-text\"> &#8220;Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS&#8221;<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":1737,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-1736","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saude","entry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS - Berit Press<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS - Berit Press\" \/>\n<meta property=\"og:description\" content=\"Fam\u00edlias de crian\u00e7as com neuroblastoma com necessidade de acesso ao medicamento de alto custo betadinutuximabe (que tem o nome comercial Qarziba) podem ter novidades neste ano.&nbsp;O laborat\u00f3rio farmac\u00eautico Recordati divulgou que submeteu esta semana&nbsp;o rem\u00e9dio \u00e0 avalia\u00e7\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (Conitec). Se aprovado, o medicamento passa &hellip; Continue lendo &quot;Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/\" \/>\n<meta property=\"og:site_name\" content=\"Berit Press\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/beritpress\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-19T13:26:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-19T13:26:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1170\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Danielly de Cassia Silva Mantovani\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@beritpress\" \/>\n<meta name=\"twitter:site\" content=\"@beritpress\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Danielly de Cassia Silva Mantovani\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/\"},\"author\":{\"name\":\"Danielly de Cassia Silva Mantovani\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#\\\/schema\\\/person\\\/05111a3cc06f383642effb7c9af06f12\"},\"headline\":\"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS\",\"datePublished\":\"2024-01-19T13:26:12+00:00\",\"dateModified\":\"2024-01-19T13:26:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/\"},\"wordCount\":682,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/beritpress.com.br\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Marcello-Casal-Jr.-Agencia-Brasil.jpg\",\"articleSection\":[\"Sa\u00fade\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/\",\"url\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/\",\"name\":\"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS - Berit Press\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/beritpress.com.br\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Marcello-Casal-Jr.-Agencia-Brasil.jpg\",\"datePublished\":\"2024-01-19T13:26:12+00:00\",\"dateModified\":\"2024-01-19T13:26:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/beritpress.com.br\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Marcello-Casal-Jr.-Agencia-Brasil.jpg\",\"contentUrl\":\"https:\\\/\\\/beritpress.com.br\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Marcello-Casal-Jr.-Agencia-Brasil.jpg\",\"width\":1170,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/2024\\\/01\\\/19\\\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/beritpress.com.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#website\",\"url\":\"https:\\\/\\\/beritpress.com.br\\\/\",\"name\":\"Berit Press\",\"description\":\"Ag\u00eancia de Comunica\u00e7\u00e3o\",\"publisher\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/beritpress.com.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#organization\",\"name\":\"Berit Press\",\"url\":\"https:\\\/\\\/beritpress.com.br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/beritpress.com.br\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/cropped-logo-beritpress.png\",\"contentUrl\":\"https:\\\/\\\/beritpress.com.br\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/cropped-logo-beritpress.png\",\"width\":190,\"height\":190,\"caption\":\"Berit Press\"},\"image\":{\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/beritpress\",\"https:\\\/\\\/x.com\\\/beritpress\",\"https:\\\/\\\/www.instagram.com\\\/agenciaberitpress\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCcTID5ZCQW5Z1fyKgSgzUWw\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/beritpress.com.br\\\/#\\\/schema\\\/person\\\/05111a3cc06f383642effb7c9af06f12\",\"name\":\"Danielly de Cassia Silva Mantovani\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a206220b317f9ad5a926145fb4edbc5915d40f5e857b6f798207decd234b735?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a206220b317f9ad5a926145fb4edbc5915d40f5e857b6f798207decd234b735?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a206220b317f9ad5a926145fb4edbc5915d40f5e857b6f798207decd234b735?s=96&d=mm&r=g\",\"caption\":\"Danielly de Cassia Silva Mantovani\"},\"url\":\"https:\\\/\\\/beritpress.com.br\\\/index.php\\\/author\\\/danielly\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS - Berit Press","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/","og_locale":"pt_BR","og_type":"article","og_title":"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS - Berit Press","og_description":"Fam\u00edlias de crian\u00e7as com neuroblastoma com necessidade de acesso ao medicamento de alto custo betadinutuximabe (que tem o nome comercial Qarziba) podem ter novidades neste ano.&nbsp;O laborat\u00f3rio farmac\u00eautico Recordati divulgou que submeteu esta semana&nbsp;o rem\u00e9dio \u00e0 avalia\u00e7\u00e3o da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (Conitec). Se aprovado, o medicamento passa &hellip; Continue lendo \"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS\"","og_url":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/","og_site_name":"Berit Press","article_publisher":"https:\/\/www.facebook.com\/beritpress","article_published_time":"2024-01-19T13:26:12+00:00","article_modified_time":"2024-01-19T13:26:14+00:00","og_image":[{"width":1170,"height":700,"url":"https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil.jpg","type":"image\/jpeg"}],"author":"Danielly de Cassia Silva Mantovani","twitter_card":"summary_large_image","twitter_creator":"@beritpress","twitter_site":"@beritpress","twitter_misc":{"Escrito por":"Danielly de Cassia Silva Mantovani","Est. tempo de leitura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/#article","isPartOf":{"@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/"},"author":{"name":"Danielly de Cassia Silva Mantovani","@id":"https:\/\/beritpress.com.br\/#\/schema\/person\/05111a3cc06f383642effb7c9af06f12"},"headline":"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS","datePublished":"2024-01-19T13:26:12+00:00","dateModified":"2024-01-19T13:26:14+00:00","mainEntityOfPage":{"@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/"},"wordCount":682,"commentCount":0,"publisher":{"@id":"https:\/\/beritpress.com.br\/#organization"},"image":{"@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/#primaryimage"},"thumbnailUrl":"https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil.jpg","articleSection":["Sa\u00fade"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/","url":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/","name":"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS - Berit Press","isPartOf":{"@id":"https:\/\/beritpress.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/#primaryimage"},"image":{"@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/#primaryimage"},"thumbnailUrl":"https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil.jpg","datePublished":"2024-01-19T13:26:12+00:00","dateModified":"2024-01-19T13:26:14+00:00","breadcrumb":{"@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/#primaryimage","url":"https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil.jpg","contentUrl":"https:\/\/beritpress.com.br\/wp-content\/uploads\/2024\/01\/Marcello-Casal-Jr.-Agencia-Brasil.jpg","width":1170,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/beritpress.com.br\/index.php\/2024\/01\/19\/laboratorio-submete-remedio-para-neuroblastoma-a-aprovacao-do-sus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/beritpress.com.br\/"},{"@type":"ListItem","position":2,"name":"Laborat\u00f3rio submete rem\u00e9dio para neuroblastoma \u00e0 aprova\u00e7\u00e3o do SUS"}]},{"@type":"WebSite","@id":"https:\/\/beritpress.com.br\/#website","url":"https:\/\/beritpress.com.br\/","name":"Berit Press","description":"Ag\u00eancia de Comunica\u00e7\u00e3o","publisher":{"@id":"https:\/\/beritpress.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beritpress.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/beritpress.com.br\/#organization","name":"Berit Press","url":"https:\/\/beritpress.com.br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/beritpress.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/beritpress.com.br\/wp-content\/uploads\/2021\/02\/cropped-logo-beritpress.png","contentUrl":"https:\/\/beritpress.com.br\/wp-content\/uploads\/2021\/02\/cropped-logo-beritpress.png","width":190,"height":190,"caption":"Berit Press"},"image":{"@id":"https:\/\/beritpress.com.br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/beritpress","https:\/\/x.com\/beritpress","https:\/\/www.instagram.com\/agenciaberitpress\/","https:\/\/www.youtube.com\/channel\/UCcTID5ZCQW5Z1fyKgSgzUWw"]},{"@type":"Person","@id":"https:\/\/beritpress.com.br\/#\/schema\/person\/05111a3cc06f383642effb7c9af06f12","name":"Danielly de Cassia Silva Mantovani","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a206220b317f9ad5a926145fb4edbc5915d40f5e857b6f798207decd234b735?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a206220b317f9ad5a926145fb4edbc5915d40f5e857b6f798207decd234b735?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a206220b317f9ad5a926145fb4edbc5915d40f5e857b6f798207decd234b735?s=96&d=mm&r=g","caption":"Danielly de Cassia Silva Mantovani"},"url":"https:\/\/beritpress.com.br\/index.php\/author\/danielly\/"}]}},"_links":{"self":[{"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/posts\/1736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/comments?post=1736"}],"version-history":[{"count":1,"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/posts\/1736\/revisions"}],"predecessor-version":[{"id":1738,"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/posts\/1736\/revisions\/1738"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/media\/1737"}],"wp:attachment":[{"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/media?parent=1736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/categories?post=1736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/beritpress.com.br\/index.php\/wp-json\/wp\/v2\/tags?post=1736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}